ATX.ASX: Amplia Receives R&D Tax Rebate Totalling $3.77 Million

Amplia Receives R&D Tax Rebate Totalling $3.77 Million

Stock	Amplia Therapeutics Ltd (ATX.ASX)
Release Time	28 Oct 2025, 9:13 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Amplia Receives $3.77M R&D Tax Rebate

Key Points

Received A$3.77M R&D tax rebate from Australian Tax Office
Rebate relates to R&D activities for FAK inhibitors narmafotinib and AMP886
Funds to support ongoing Phase 1b/2a clinical trials of narmafotinib

Full Summary

Amplia Therapeutics Limited (ASX: ATX) has received A$3,771,706 via the Research and Development Tax Incentive from the Australian Tax Office for the financial year ended 31 March 2025. The R&D tax rebate relates to expenditure incurred in R&D activities associated with the company's FAK inhibitors, narmafotinib (AMP945) and AMP886. These activities primarily related to Amplia's ongoing Phase 1b/2a clinical trials of narmafotinib in advanced pancreatic cancer patients. The funds will contribute to the further progression of both the ACCENT and AMPLICITY clinical trials of narmafotinib along with additional supporting R&D activities. The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with a tax offset of 43.5%-48.5% (refundable) for eligible expenditure on R&D activities.